Financial Performance - The company's revenue for 2024 reached ¥544,471,262.04, representing an increase of 11.18% compared to ¥489,717,074.89 in 2023[20]. - Net profit attributable to shareholders decreased by 54.59% to ¥17,083,154.83 in 2024 from ¥37,619,249.09 in 2023[20]. - The net profit after deducting non-recurring gains and losses fell by 82.74% to ¥4,957,358.15 in 2024 from ¥28,726,211.38 in 2023[20]. - Operating cash flow net amount surged by 287.68% to ¥80,863,529.75 in 2024 from ¥20,858,397.98 in 2023[20]. - Basic earnings per share decreased by 55.56% to ¥0.12 in 2024 from ¥0.27 in 2023[20]. - Total assets at the end of 2024 were ¥1,316,426,388.19, a decrease of 11.48% from ¥1,487,163,922.77 at the end of 2023[20]. - The company's net assets attributable to shareholders decreased by 7.59% to ¥1,032,697,457.80 at the end of 2024 from ¥1,117,544,666.53 at the end of 2023[20]. - The company reported a significant increase in cash flow from operating activities in the first quarter of 2024, amounting to ¥9,275,848.83[22]. - The company experienced a net loss attributable to shareholders in the third quarter of 2024, amounting to -¥732,885.31[22]. Research and Development (R&D) - R&D expenses increased year-on-year, reflecting the company's ongoing investment in research and technology platforms[4]. - Research and development (R&D) expenses for 2024 are reported at 4,726.10 million, reflecting a CAGR of 40.21% from 2022 to 2024[57]. - R&D expenses accounted for 8.68% of total revenue in 2024, up from 6.82% in 2022[57]. - The number of R&D personnel in 2024 is 668, representing 66.53% of the total workforce of 1,004 employees[58]. - The company has maintained a high R&D personnel ratio of over 50% over the past three years, ensuring a strong technical foundation[58]. - The company has established a comprehensive new drug R&D platform, incorporating advanced technologies such as high-throughput screening and artificial intelligence-assisted drug design[62]. - The company has applied for 14 new patents during the reporting period, including 7 invention patents and 7 utility model patents[65]. - The company has developed advanced technologies related to drug discovery and process development, including CADD/AIDD (computer/AI-assisted drug design) and targeted delivery technology for small nucleic acid drugs[65]. - The company has a strong focus on R&D, with numerous patents related to antiviral compounds and methods for preparing key intermediates for various drugs[66]. Market and Industry Trends - The global pharmaceutical market size increased from $1,324.5 billion in 2019 to $1,472.3 billion in 2023, with projections of $1,766.7 billion by 2026 and $2,069.4 billion by 2030[30]. - China's pharmaceutical market reached $231.5 billion in 2023, expected to grow to $291.1 billion by 2026 and $373.2 billion by 2030, marking a significant phase of innovation[30]. - The global CRO market grew from $53.91 billion in 2018 to $77.57 billion in 2022, with a projected CAGR of 9.1% to reach $158.36 billion by 2030[32]. - China's CRO market expanded from ¥36.49 billion in 2018 to ¥81.37 billion in 2022, with a projected CAGR of 14.0% to reach ¥275.77 billion by 2030[32]. - The R&D outsourcing penetration rate for the top 20 global pharmaceutical companies reached 54% in 2023, while biotech companies' outsourcing expenditure exceeded 75%[32]. Operational Efficiency and Strategy - For the fiscal year 2025, the company plans to enhance profitability through various measures, including strengthening technological reserves and expanding market reach[6]. - The company aims to improve production efficiency and profitability by optimizing manufacturing processes and workflows[6]. - The company focuses on enhancing production efficiency and quality control during the transition from small-scale to large-scale drug production[54]. - The company aims to leverage its R&D capabilities to support the commercialization of new drugs and expand its market presence[53]. - The company is actively pursuing new product development and technological innovations to strengthen its market position[66]. Financial Management and Fundraising - The company has engaged CITIC Securities as its sponsor for the period from November 1, 2022, to December 31, 2025[20]. - The company has reported a year-end balance of restricted assets amounting to RMB 25,392,713.80, with various types of collateral including bank acceptance bills and mortgages[127]. - The company has committed to invest a total of 38.7 million in clinical research and development projects by the end of 2022[137]. - The company has successfully raised additional funds amounting to 6.47 million, fully allocated for development and operational needs[137]. - The company plans to use up to RMB 400 million of temporarily idle raised funds for cash management, with a usage period not exceeding 12 months[139]. Governance and Management - The current management team includes experienced professionals with backgrounds in pharmaceuticals and finance, enhancing the company's strategic direction[173][174][175][176][177][178][179][180]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[10]. - The board of directors held a total of 20 meetings during the reporting period, with the latest meeting on October 31, 2024[198][199]. - The company is committed to maintaining high governance standards, as evidenced by the active participation of its board members[200]. - The board's engagement in strategic discussions reflects its proactive approach to corporate governance[200]. Risks and Challenges - The company faces risks related to market competition, particularly in the commercialization of its main product, Ticagrelor, as patent protections expire[151]. - There is a risk of declining gross profit margins due to rising labor costs and increased competition in the CRO sector[152]. - Environmental and safety risks are present due to the production processes of its subsidiary, which may lead to regulatory penalties[153]. - Interest rate fluctuations pose a potential risk to the company's financial stability[156]. - The company's commercialization is heavily reliant on Ticagrelor, leading to risks associated with product concentration[155].

■■■■■301230■■■■2024国■■■■5.44国■■■■■11.18％■■■■■■■■■■■■■■■■■■■■1708.32■■■■■■■0.12星/回■■■■■■■■■■■■■■■■■■■■■■■■■■■■10 ...

创新药概念震荡拉升，海南海药（000566）涨停，一品红（300723）、泓博医药（301230）、科兴制 药、海正药业（600267）、中源协和（600645）等跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-022 上海泓博智源医药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在新增、修改、否决议案的情形； 2、本次股东大会不存在变更前次股东大会决议的情形； 3、本次股东大会采取现场投票与网络投票相结合的方式进行。 一、会议召开情况 1、会议通知方式：公告方式 2、会议召开时间： （1）现场会议召开时间：2025 年 3 月 20 日（星期四）14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 3 月 20 日上午 9:15~9:25，9:30~11:30 和下午 13:00~15:00；通过深圳证券交易所互联网 投票系统投票的具体时间为 2025 年 3 月 20 日 9:15～15:00 任意时间。 二、会议出席情况 1、出席会议股东的总体情况 参加本次股东大会表决的股东共计 47 人，代表股份 52,471,602 股，占公司有表决 权股份总数的 38.1500％。其 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-021 上海泓博智源医药股份有限公司 关于选举职工代表监事的公告 2025 年 3 月 20 日 附件： 何晓晶女士个人简历 何晓晶，女，1986 年 10 月出生，中国国籍，无境外永久居留权，大学本科学历。 2009 年 7 月毕业于南京医科大学药学专业，获学士学位。2009 年 7 月至今，就职于泓 博医药，现任分析研发部副总监，2019 年 12 月至今，任泓博医药监事。 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海泓博智源医药股份有限公司（以下简称"公司"或"泓博医药"）第三届监事 会任期届满，根据《公司法》《公司章程》等有关规定，公司于2025年3月19日召开了 职工代表大会。经参会代表认真讨论，一致同意选举何晓晶女士、李红海先生为公司第 四届监事会职工代表监事（简历详见附件），届时将与公司2025年第一次临时股东大会 选举产生的3名非职工代表监事共同组成公司第四届监事会，任期三年。 何晓晶女士和李红海先生符合《公司法》《公司章程》规定的有关监事任职资格和 条件。公司第四届监事会 ...

北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 法律意见书 嘉源(2025)-04-151 EUM == Ph YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:上海泓博智源医药股份有限公司 北京市嘉源律师事务所 关于上海泓博智源医药股份有限公司 2025 年第一次临时股东大会的 北京市嘉源律师事务所(以下简称"本所")接受上海泓博智源医药股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简称 "《公司法》")《上市公司股东大会规则》(以下简称"《股东大会规则》")等现行 有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规")以及 《上海泓博智源医药股份有限公司章程》(以下简称"《公司章程》")的有关规定, 指派本所律师对公司 2025 年第一次临时股东大会(以下简称"本次股东大会") 进行见证,并依法出具本法 ...

证券代码：301230 证券简称：泓博医药 公告编号：2025-020 一、对外投资概述 上海泓博智源医药股份有限公司（以下简称"公司"）为满足公司发展战略需要， 与上海骊辕企业管理合伙企业（有限合伙）、上海骊宸元鼎私募投资基金合伙企业 （有限合伙）签订《上海骊宸延和企业管理合伙企业（有限合伙）合伙协议》，共同 出资设立上海骊宸延和企业管理合伙企业（有限合伙）（以下简称"骊宸延和"）。 公司以自有资金认缴出资730万元，占出资比例的28.08%。 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监 管指引第2号——创业板上市公司规范运作》及《上海泓博智源医药股份有限公司章 程》等相关规定，本次对外投资不需要公司董事会、股东大会的审议批准。 本次对外投资不会导致同业竞争且不构成关联交易，也不构成《上市公司重大资产 重组管理办法》等相关规定涉及的重大资产重组。 上海泓博智源医药股份有限公司 关于对外投资设立有限合伙企业的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 近日，骊宸延和已完成工商变更登记，具体情况如下： 二、合作方基本情况 ...

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The report highlights significant stock performance in the sector, with the pharmaceutical and biotechnology sector (SW) rising by 2.71%, outperforming the CSI 300 index, and all sub-sectors showing positive growth, particularly in medical services [3][4]. - In the U.S., Tempus AI, a representative company in medical AI, saw a weekly increase of approximately 30% and over 160% year-to-date, driving the momentum of the medical AI concept. In China, companies like KingMed Diagnostics and Dian Diagnostics announced collaborations with DeepSeek, indicating a shift towards the commercialization of AI applications in healthcare [4][3]. - The report emphasizes investment opportunities in sub-sectors such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI Genomics, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% in the week of February 10-14, ranking 5th among 31 Shenwan primary industries. The CSI 300 index increased by 1.19% during the same period [5][6]. - All sub-sectors experienced growth, with medical services leading at +6.51%, followed by medical devices at +4.81%, and pharmaceutical commerce at +4.18% [5][6]. - Notable individual stock performances included Dian Diagnostics (+46.29%), Mian Health (+31.58%), and United Imaging (+27.33%) [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - The retail terminal drug sales scale in China is projected to reach 574 billion yuan in 2024, with a growth rate of 3.7%, indicating a slowdown in growth due to demographic and economic factors [8]. - The report also notes significant collaborations, such as Baiyang Pharmaceutical's agreement with Roche for the exclusive marketing rights of a targeted cancer drug in mainland China [9][11]. Industry Data Tracking - The report tracks various industry metrics, including the basic medical insurance fund income, which reached 28,507.29 billion yuan in 2024, showing a year-on-year growth of 5% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of 25,298.50 billion yuan in 2024, with profit totals declining by 1.1% year-on-year [17].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [5] Core Viewpoints - The AI concept has experienced a pullback, but the upward momentum for innovative drugs is expected to continue [1][2] - The pharmaceutical index fell by 2.15% last week, outperforming the CSI 300 index by 0.07 percentage points, ranking 25th in industry performance [10] - The healthcare services sub-sector has shown the highest growth since the beginning of 2025, with a rise of 12.31% [16] - The report highlights the strong performance of innovative drugs and companies with positive earnings forecasts, such as Nocera Health and Newnovel [19][31] Market Performance Summary - The pharmaceutical index has increased by 4.17% year-to-date, outperforming the CSI 300 index by 5.31 percentage points, ranking 12th in industry performance [10] - The best-performing stocks in the A-share market last week included Nocera Health (+20.98%), Changyao Holdings (+20.96%), and Shanghai Yizhong (+18.78%) [19] - In the Hong Kong stock market, 30 out of 106 pharmaceutical stocks rose, accounting for 28.3% [23] Sub-industry Performance - The sub-industry with the smallest decline last week was Traditional Chinese Medicine, down 0.35%, while the largest decline was in pharmaceutical commerce, down 3.44% [14] - Year-to-date, the Traditional Chinese Medicine sub-sector has decreased by 5.29%, while healthcare services have increased by 12.31% [16] Industry News and Policies - Starting March 1, Guangxi will implement centralized procurement for large medical equipment, aiming to reduce costs through bulk purchasing [27][28] - Huadong Medicine's ADC innovative drug has received orphan drug designation from the FDA, which provides various incentives for the company [29] Company Announcements - Notable company announcements include Nocera Health's significant R&D progress and Newnovel's exclusive cooperation agreement with RadianceBiopharma, potentially worth $1.23 billion [19][31]

Investment Rating - The report assigns an investment rating of "Recommended" for the pharmaceutical and biotechnology industry [3][33]. Core Insights - The "AI + Healthcare/Pharmaceutical" theme continues to gain traction, with short-term momentum expected to persist. The domestic and international markets are witnessing significant developments in AI applications within healthcare, particularly with companies like Tempus AI showing substantial stock price increases [3][4]. - The report highlights investment opportunities in specific segments such as "AI + Medical Imaging," "AI + Diagnostic Services," and "AI + Drug Development," recommending key companies including United Imaging, Mindray, BGI, and WuXi AppTec [3][4]. Industry Performance Tracking - The pharmaceutical and biotechnology sector (SW) rose by 2.71% last week, outperforming the CSI 300 index, which increased by 1.19%. All sub-sectors within the industry experienced growth, with medical services leading at +6.51% [5][6]. - Notable individual stock performances included Dean Diagnostics (+46.29%) and Meinian Health (+31.58%), while stocks like Betta Pharmaceuticals saw declines of -11.36% [6]. Industry Dynamics and Key Company Tracking - The National Healthcare Security Administration released a list of key tasks for 2025, focusing on efficient medical insurance processes and direct settlements for collected drugs and consumables [7]. - Recent collaborations include Baiyang Pharmaceutical signing a commercialization agreement with Roche for the drug Rituximab, and Sanofi Biologics partnering with Baili Tianheng to explore new treatment potentials in oncology [11][12]. Industry Data Tracking - The retail terminal drug sales in China are projected to reach CNY 574 billion in 2024, with a growth rate of 3.7%, indicating a slowdown compared to previous years [8]. - The medical insurance fund's income for 2024 is reported at CNY 28,507.29 billion, reflecting a year-on-year growth of 5.00% [15][16]. - The domestic pharmaceutical manufacturing industry achieved a total revenue of CNY 25,298.50 billion in 2024, remaining stable compared to the previous year [17].